Immunotherapy in multiple myeloma

Irene M. Hutchins, Levanto Schachter, Anuj K. Mahindra

Research output: Contribution to journalReview article

Abstract

Therapeutic approaches in multiple myeloma (MM) are increasingly focused on restoring antitumor immunity. Immunomodulators have a variety of effects on the immune microenvironment, and are frequently incorporated into multidrug regimens. The monoclonal antibodies daratumumab and elotuzumab have been granted accelerated approval for use in the relapsed or refractory setting, and several other antibodies including immune checkpoint inhibitors are currently being evaluated for the treatment of MM. Antimyeloma vaccines have been developed, and may be useful in maintaining remission. The role of allogeneic stem cell transplantation continues to be an area of active research, as reduced intensity conditioning (RIC) regimens have significantly decreased treatment-related complications. Other immunotherapeutic approaches in development include marrow infiltrating lymphocytes, T cell receptor modified T cells (TCRts), and chimeric antigen receptor (CAR) T cells. Here we review the existing data on immunotherapy in MM, and discuss some promising areas of research which may impact the future of myeloma therapy.

Original languageEnglish (US)
Pages (from-to)109-116
Number of pages8
JournalTranslational Cancer Research
Volume6
Issue number1
DOIs
StatePublished - Jan 1 2017
Externally publishedYes

Fingerprint

Multiple Myeloma
Immunotherapy
T-Cell Antigen Receptor
Immunologic Factors
Stem Cell Transplantation
Therapeutics
Research
Immunity
Vaccines
Bone Marrow
Monoclonal Antibodies
Lymphocytes
T-Lymphocytes
Antibodies

Keywords

  • Antibodies
  • Antigen
  • Immunotherapy
  • Monoclonal
  • Multiple myeloma (MM)
  • Receptors
  • Stem cell transplantation
  • T-cell

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Cite this

Immunotherapy in multiple myeloma. / Hutchins, Irene M.; Schachter, Levanto; Mahindra, Anuj K.

In: Translational Cancer Research, Vol. 6, No. 1, 01.01.2017, p. 109-116.

Research output: Contribution to journalReview article

Hutchins, Irene M. ; Schachter, Levanto ; Mahindra, Anuj K. / Immunotherapy in multiple myeloma. In: Translational Cancer Research. 2017 ; Vol. 6, No. 1. pp. 109-116.
@article{b1ab10d0efb84f309374e0d36cd675d0,
title = "Immunotherapy in multiple myeloma",
abstract = "Therapeutic approaches in multiple myeloma (MM) are increasingly focused on restoring antitumor immunity. Immunomodulators have a variety of effects on the immune microenvironment, and are frequently incorporated into multidrug regimens. The monoclonal antibodies daratumumab and elotuzumab have been granted accelerated approval for use in the relapsed or refractory setting, and several other antibodies including immune checkpoint inhibitors are currently being evaluated for the treatment of MM. Antimyeloma vaccines have been developed, and may be useful in maintaining remission. The role of allogeneic stem cell transplantation continues to be an area of active research, as reduced intensity conditioning (RIC) regimens have significantly decreased treatment-related complications. Other immunotherapeutic approaches in development include marrow infiltrating lymphocytes, T cell receptor modified T cells (TCRts), and chimeric antigen receptor (CAR) T cells. Here we review the existing data on immunotherapy in MM, and discuss some promising areas of research which may impact the future of myeloma therapy.",
keywords = "Antibodies, Antigen, Immunotherapy, Monoclonal, Multiple myeloma (MM), Receptors, Stem cell transplantation, T-cell",
author = "Hutchins, {Irene M.} and Levanto Schachter and Mahindra, {Anuj K.}",
year = "2017",
month = "1",
day = "1",
doi = "10.21037/tcr.2017.01.34",
language = "English (US)",
volume = "6",
pages = "109--116",
journal = "Translational Cancer Research",
issn = "2218-676X",
publisher = "AME Publishing Company",
number = "1",

}

TY - JOUR

T1 - Immunotherapy in multiple myeloma

AU - Hutchins, Irene M.

AU - Schachter, Levanto

AU - Mahindra, Anuj K.

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Therapeutic approaches in multiple myeloma (MM) are increasingly focused on restoring antitumor immunity. Immunomodulators have a variety of effects on the immune microenvironment, and are frequently incorporated into multidrug regimens. The monoclonal antibodies daratumumab and elotuzumab have been granted accelerated approval for use in the relapsed or refractory setting, and several other antibodies including immune checkpoint inhibitors are currently being evaluated for the treatment of MM. Antimyeloma vaccines have been developed, and may be useful in maintaining remission. The role of allogeneic stem cell transplantation continues to be an area of active research, as reduced intensity conditioning (RIC) regimens have significantly decreased treatment-related complications. Other immunotherapeutic approaches in development include marrow infiltrating lymphocytes, T cell receptor modified T cells (TCRts), and chimeric antigen receptor (CAR) T cells. Here we review the existing data on immunotherapy in MM, and discuss some promising areas of research which may impact the future of myeloma therapy.

AB - Therapeutic approaches in multiple myeloma (MM) are increasingly focused on restoring antitumor immunity. Immunomodulators have a variety of effects on the immune microenvironment, and are frequently incorporated into multidrug regimens. The monoclonal antibodies daratumumab and elotuzumab have been granted accelerated approval for use in the relapsed or refractory setting, and several other antibodies including immune checkpoint inhibitors are currently being evaluated for the treatment of MM. Antimyeloma vaccines have been developed, and may be useful in maintaining remission. The role of allogeneic stem cell transplantation continues to be an area of active research, as reduced intensity conditioning (RIC) regimens have significantly decreased treatment-related complications. Other immunotherapeutic approaches in development include marrow infiltrating lymphocytes, T cell receptor modified T cells (TCRts), and chimeric antigen receptor (CAR) T cells. Here we review the existing data on immunotherapy in MM, and discuss some promising areas of research which may impact the future of myeloma therapy.

KW - Antibodies

KW - Antigen

KW - Immunotherapy

KW - Monoclonal

KW - Multiple myeloma (MM)

KW - Receptors

KW - Stem cell transplantation

KW - T-cell

UR - http://www.scopus.com/inward/record.url?scp=85013873791&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85013873791&partnerID=8YFLogxK

U2 - 10.21037/tcr.2017.01.34

DO - 10.21037/tcr.2017.01.34

M3 - Review article

VL - 6

SP - 109

EP - 116

JO - Translational Cancer Research

JF - Translational Cancer Research

SN - 2218-676X

IS - 1

ER -